Long-term complications of platinum-based chemotherapy in testicular cancer survivors

2007 ◽  
Vol 24 (2) ◽  
pp. 175-181 ◽  
Author(s):  
J. H. Oh ◽  
D. D. Baum ◽  
S. Pham ◽  
M. Cox ◽  
S. T. Nguyen ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Cancer Survivors ◽  
Platinum Based Chemotherapy ◽  
Testicular Cancer Survivors

scholarly journals Treatment-related cardiovascular toxicity in long-term survivors of testicular cancer

2017 ◽  
Vol 51 (2) ◽  
pp. 221-227 ◽  
Author(s):  
Jasenka Gugic ◽  
Lorna Zadravec Zaletel ◽  
Irena Oblak
Keyword(s):  
Testicular Cancer ◽  
Cancer Survivors ◽  
Major Complication ◽  
Treatment Modalities ◽  
Cardiovascular Toxicity ◽  
Platinum Based Chemotherapy ◽  
Short Period ◽  
Modern Treatment ◽  
Testicular Cancer Survivors

Abstract Backgrounds Testicular cancer is the most common malignancy in young men. Considering increasing incidence, exceptionally high cure rate, as well as long life expectancy, assessment of long term toxicity in testicular cancer survivors is of great importance. In the last decades a major effort has been made in order to reduce toxicity of treatment, while maintaining its high effectiveness. Conclusions Actual knowledge on treatment toxicity is based on outdated treatment modalities. Hopefully, modern treatment modalities could reduce toxicity, but, there is no firm confirmation for that at the moment, as data dealing with late sequelae of modern treatment of testicular cancer are not available yet due to the short period of observation. The life-threatening cardiovascular toxicity in testicular cancer survivors is major complication of platinum-based chemotherapy, mediastinal radiotherapy and even subdiaphragmatic radiotherapy.

Long-term complications of platinum in testicular cancer survivors

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 4589-4589
Author(s):  
J. H. Oh ◽  
D. D. Baum ◽  
J. Ensor ◽  
S. Pham ◽  
M. D. Muddiman ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Cancer Survivors ◽  
Treatment Modalities ◽  
Platinum Based Chemotherapy ◽  
Blood Pressure Treatment ◽  
The Mean ◽  
Testicular Cancer Survivors ◽  
All Treatment

4589 Background: Long-term medical complications of platinum have become a major priority in the care of testicular cancer survivors. This study aimed to describe the prevalence of these complications from platinum-based therapy in American testicular cancer survivors. Methods: Testicular cancer survivors with no evidence of disease for at least 2 years were interviewed, had lab tests, and charts reviewed. Demographics, comorbidities, blood pressure, treatment, and outcomes were compared between all treatment modalities. NHANES 2002 and NHIS 2004 were used to obtain national estimates. Results: The mean age was 41 years; 72.7 % had nonseminoma, 96.5% had orchiectomy, 21.0% received radiation (XRT), and 82.5% platinum. The mean follow-up was 8.4 years. There was no statistical difference in the rates of Coronary Artery Disease (CAD), hyperlipidemia, hypertension (HTN), renal insufficiency (RI), or hypomagnesemia (see table ). There was a trend toward an increase in hyperlipidemia at follow-up compared to initial visit in all treatment groups but HTN increased only in those who did not receive platinum. Conclusion: Excluding HTN, we observed a trend toward an increase in the prevalence of RI, hypomagnesemia, hyperlipidemia, and CAD among patients who received platinum when compared to their baseline rates. Similar to a recent study by Huddart et al, we saw a trend toward higher risk of developing CAD in those who received both platinum and XRT. These findings suggest that hyperlipidemia and HTN may be more related to orchiectomy or the germ cell tumor itself than being a complication of platinum. Further prospective cohort studies with a larger group of survivors who have not received platinum are warranted to determine if HTN and hyperlipidemia are true complications of platinum-based chemotherapy. [Table: see text] No significant financial relationships to disclose.

A study of coping in long-term testicular cancer survivors

2010 ◽  
Vol 15 (2) ◽  
pp. 146-158 ◽  
Author(s):  
Robert Rutskij ◽  
Torfinn Gaarden ◽  
Roy Bremnes ◽  
Olav Dahl ◽  
Arnstein Finset ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Cancer Survivors ◽  
Testicular Cancer Survivors

Cisplatin-Induced Long-Term Hearing Impairment Is Associated With Specific Glutathione S-Transferase Genotypes in Testicular Cancer Survivors

2007 ◽  
Vol 25 (6) ◽  
pp. 708-714 ◽  
Author(s):  
Jan Oldenburg ◽  
Sigrid M. Kraggerud ◽  
Milada Cvancarova ◽  
Ragnhild A. Lothe ◽  
Sophie D. Fossa
Keyword(s):  
Testicular Cancer ◽  
Cancer Survivors ◽  
Hearing Impairment ◽  
Glutathione S Transferase ◽  
Functional Polymorphisms ◽  
Hearing Ability ◽  
Interindividual Variations ◽  
Glutathione S Transferases ◽  
Testicular Cancer Survivors

Purpose Cisplatin, a cornerstone of combination chemotherapy in the treatment of testicular cancer, induces hearing impairment with considerable interindividual variations. These differences might be a result of functional polymorphisms in cisplatin-detoxifying enzymes like glutathione S-transferases (GSTs). Patients and Methods We identified 173 cisplatin-treated testicular cancer survivors (TCSs) who had participated in a long-term survey that included audiometric testing and lymphocyte sampling. The hearing decibel thresholds at 4,000 Hz were categorized into leveled scales by normative decibel percentiles. Known functional polymorphisms (positive or negative) in GSTT1 and GSTM1 and codon 105 A/G (Ile/Val) in GSTP1 were analyzed by multiplex polymerase chain reaction, followed by restriction enzyme cutting, and separated by gel electrophoresis. Results The risk of having an inferior audiometric result was more than four times higher in TCSs with 105Ile/105Ile-GSTP1 or 105Val/105Ile-GSTP1 compared with 105Val/105Val-GSTP1 (odds ratio [OR] = 4.21; 95% CI, 1.99 to 8.88; P < .001 when modeled by ordinal logistic regression [OLR]). GSTM1 positivity was detrimental for hearing ability. Two combined genotypes were associated with hearing ability. The presence of pattern 1 (GSTT1 positive, GSTM1 positive, and 105Ile/105Ile-GSTP1) was associated with hearing impairment (OR = 2.76; 95% CI, 1.35 to 5.64; P = .005, OLR). TCSs with pattern 2 (GSTT1 positive, GSTM1 positive, and 105Val/105Val-GSTP1) had better hearing ability than TCSs without this pattern (OR = 5.35; 95% CI, 2.25 to 12.76; P < .001, OLR). Conclusion The presence of both alleles of 105Val-GSTP1 offered protection against cisplatin-induced hearing impairment. Two genotype patterns with good and poor protection against cisplatin-induced ototoxicity were identified.

scholarly journals Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: increasing prevalence and risk factors

2015 ◽  
Vol 26 (10) ◽  
pp. 2133-2140 ◽  
Author(s):  
M. Sprauten ◽  
H.S. Haugnes ◽  
M. Brydøy ◽  
C. Kiserud ◽  
T. Tandstad ◽  
...  
Keyword(s):  
Risk Factors ◽  
Testicular Cancer ◽  
Cancer Survivors ◽  
Chronic Fatigue ◽  
Long Term Follow Up ◽  
Testicular Cancer Survivors

scholarly journals Long-Term Follow Up of the Erectile Function of Testicular Cancer Survivors

2019 ◽  
Vol 10 ◽  
Author(s):  
Francesco Pallotti ◽  
Alessandra Petrozzi ◽  
Francesco Cargnelutti ◽  
Antonio Francesco Radicioni ◽  
Andrea Lenzi ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Cancer Survivors ◽  
Erectile Function ◽  
Long Term Follow Up ◽  
Testicular Cancer Survivors

scholarly journals The personality trait of neuroticism is strongly associated with long-term morbidity in testicular cancer survivors

2009 ◽  
Vol 48 (6) ◽  
pp. 842-849 ◽  
Author(s):  
Ellen Karine Grov ◽  
Sophie D. Fosså ◽  
Roy M. Bremnes ◽  
Olav Dahl ◽  
Olbjørn Klepp ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Cancer Survivors ◽  
Personality Trait ◽  
Testicular Cancer Survivors

scholarly journals Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors

2018 ◽  
Vol 2018 ◽  
pp. 1-20 ◽  
Author(s):  
Chunkit Fung ◽  
Paul Dinh ◽  
Shirin Ardeshir-Rouhani-Fard ◽  
Kerry Schaffer ◽  
Sophie D. Fossa ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Testicular Cancer ◽  
Cancer Survivors ◽  
Current Status ◽  
Malignant Neoplasms ◽  
Targeted Prevention ◽  
Care Providers ◽  
National Guidelines ◽  
Testicular Cancer Survivors

Testicular cancer has become the paradigm of adult-onset cancer survivorship, due to the young age at diagnosis and 10-year relative survival of 95%. This clinical review presents the current status of various treatment-related complications experienced by long-term testicular cancer survivors (TCS) free of disease for 5 or more years after primary treatment. Cardiovascular disease and second malignant neoplasms represent the most common potentially life-threatening late effects. Other long-term adverse outcomes include neuro- and ototoxicity, pulmonary complications, nephrotoxicity, hypogonadism, infertility, and avascular necrosis. Future research efforts should focus on delineation of the genetic underpinning of these long-term toxicities to understand their biologic basis and etiopathogenetic pathways, with the goal of developing targeted prevention and intervention strategies to optimize risk-based care and minimize chronic morbidities. In the interim, health care providers should advise TCS to adhere to national guidelines for the management of cardiovascular disease risk factors, as well as to adopt behaviors consistent with a healthy lifestyle, including smoking cessation, a balanced diet, and a moderate to vigorous intensity exercise program. TCS should also follow national guidelines for cancer screening as currently applied to the general population.

Sign in / Sign up

Export Citation Format

Share Document